Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats.

The objective of the present study was to evaluate the effects of formulation parameters on the in vivo pharmacological activity of the chitosan-insulin nanoparticles. Chitosan-insulin nanoparticles were prepared by ionotropic gelation at pH 5.3 and 6.1 and denoted as F5.3 np and F6.1 np, respectively. F5.3 np and F6.1 np administered orally at insulin doses of 50 U/kg and/or 100 U/kg were effective at lowering the serum glucose level of streptozotocin-induced diabetic rats. The 100 U/kg-dose F5.3 np sustained the serum glucose at pre-diabetic levels for at least 11 h. In comparison, F6.1 np had a faster onset of action (2h versus 10h) but lower efficiency. The effectiveness of peroral F5.3 np and F6.1 np in lowering the serum glucose level of streptozotocin-induced diabetic rats was ascribed to the local effect of insulin in intestine. Confocal micrographs showed strong interaction between rat intestinal epithelium and chitosan nanoparticles 3h post-oral administration.

[1]  Akira Yamamoto,et al.  Penetration and enzymatic barriers to peptide and protein absorption , 1989 .

[2]  P. Artursson,et al.  Chitosans as Absorption Enhancers for Poorly Absorbable Drugs 2: Mechanism of Absorption Enhancement , 1997, Pharmaceutical Research.

[3]  Sek-Man Wong,et al.  The degree of deacetylation of chitosan: advocating the first derivative UV-spectrophotometry method of determination. , 1998, Talanta.

[4]  N. Gallo‐Payet,et al.  Insulin receptors in isolated adult mouse intestinal cells: studies in vivo and in organ culture. , 1984, Endocrinology.

[5]  P. Couvreur,et al.  New Approach for Oral Administration of Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier , 1988, Diabetes.

[6]  Min Huang,et al.  Uptake of FITC-Chitosan Nanoparticles by A549 Cells , 2002, Pharmaceutical Research.

[7]  E. Mathiowitz,et al.  Nanosphere based oral insulin delivery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[8]  P. Couvreur,et al.  Insulin‐loaded nanocapsules for oral administration: In vitro and in vivo investigation , 2000 .

[9]  Hui Xu,et al.  Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. , 2002, International journal of pharmaceutics.

[10]  P. Lowe,et al.  Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats , 1994, The Journal of pharmacy and pharmacology.

[11]  H. Junginger,et al.  Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers , 1997 .

[12]  M. Morishita,et al.  Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. , 1999, Drug development and industrial pharmacy.

[13]  H. Junginger,et al.  Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro , 1997 .

[14]  C. Remuñán-López,et al.  Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles , 1999, Pharmaceutical Research.

[15]  S. Bo,et al.  Determination of the Mark-Houwink equation for chitosans with different degrees of deacetylation. , 1991, International journal of biological macromolecules.

[16]  A. Jamal,et al.  Regulation of mucosal phosphofructokinase in the small intestine of the streptozotocin-diabetic rat , 1983, Diabetologia.

[17]  Per Artursson,et al.  Chitosans as Absorption Enhancers for Poorly Absorbable Drugs. 1: Influence of Molecular Weight and Degree of Acetylation on Drug Transport Across Human Intestinal Epithelial (Caco-2) Cells , 1996, Pharmaceutical Research.

[18]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[19]  Claus-Michael Lehr,et al.  In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers , 1992 .

[20]  Lisbeth Illum,et al.  Chitosan as a Novel Nasal Delivery System for Peptide Drugs , 1994, Pharmaceutical Research.

[21]  L. Lim,et al.  Formulation pH modulates the interaction of insulin with chitosan nanoparticles. , 2002, Journal of pharmaceutical sciences.

[22]  T. Csáky,et al.  Intestinal Sugar Transport in Experimental Diabetes , 1981, Diabetes.